Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06176599
Other study ID # YXLL-KY-2023(137)
Secondary ID YXLL-KY-2023(137
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date June 30, 2024

Study information

Verified date December 2023
Source Qianfoshan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore the therapeutic effect of Shenxiao Yuning Decoction on albuminuria and the improvement of traditional Chinese medicine syndrome in patients with stage III diabetic kidney disease with Qi and Yin deficiency and blood stasis syndrome.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Meet the diagnostic criteria for albuminuria in type 2 diabetic nephropathy, persistent albuminuria, and 2 consecutive urine microalbumin/creatinine (ACR) >30mg/g within 3 months; - The glomerular filtration rate eGPR = 60ml/min/1.73m2, and is required to remain stable during the trial (eGFR decreases =25% from the beginning of screening to the second week of follow-up); - Those who are consistent with the syndrome of diabetes and kidney disease, deficiency of Qi and Yin and blood stasis; - Gender is not limited, age is 18-75 years old, BMI=45 kg/m2; - Glycated hemoglobin (HbA1C) 6-11%, fasting blood glucose (FPG) =15 mmol/L; - Systolic blood pressure/diastolic blood pressure (SBP/DBP) =180/100 mmhg (sitting); - Those who have complete medical records, voluntarily participate in this clinical study, and sign the informed consent form. Exclusion Criteria: - Pregnant and lactating women; - Acute complications of diabetes such as hypoglycemic coma, diabetic ketosis, lactic acidosis, etc. have recently occurred; - Those combined with heart failure and myocardial infarction; combined with infections, immune diseases, and malignant tumors; combined with liver diseases (ALT, AST or ALP levels exceed three times the upper limit of normal); - Male serum creatinine (SCr) =1.50 mg/d1 (114.4 µmol/L), or female serum creatinine =1.40 mg/dl (106.8 µmol/L); - Those who are combined with other kidney and renovascular diseases, or those who have other causes such as excessive exercise, heart failure, febrile infections, or urinary tract infections that lead to elevated urinary microalbumin; - Those who have used nephrotoxic drugs and antioxidants, or used systemic glucocorticoid therapy in the past 2 weeks; - Those undergoing dialysis or kidney transplantation; - History of bariatric surgery or other gastrointestinal surgery causing chronic malabsorption within 2 years; - Persons with drug contraindications: pregnant or lactating women, allergic constitutions, and those allergic to the drugs used in this study; - Those who are unable to cooperate due to severe mental illness or mental disorder; - Those who have not signed the informed consent form.

Study Design


Intervention

Drug:
Shenxiao Yuning decoction
Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g,Cimicifuga 15g,Cuttlebone 15g,Poria 15g,Cicada degeneration 9g,Rheum palmatum 6g.
Symptomatic treatment
(i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure >140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, a, ß-blockers, diuretics, etc.); ? Other symptomatic treatment.

Locations

Country Name City State
China The First Affiliated Hospital of Shandong First Medical University Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Lin Liao

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effective rate Clinical control: Urine routine examination of urine protein qualitative turn negative, ACR normal. Apparent effect: ACR reduction =50%. Effective: ACR reduction =15%, but less than =50%. Ineffective No improvement in clinical manifestations and laboratory parameters. 0 week,4 weeks
Secondary Urinary a1-MG Charge patients for random urine measurements Urinary a1-MG 0 week,4 weeks
Secondary Urinary ß2-MG Collect random urine measurements from patients Urinary ß2-MG 0 week,4 weeks
Secondary Scr Collect the patient's fasting blood to measure Scr 0 week,4 weeks
Secondary BUN Collect the patient's fasting blood to measure BUN 0 week,4 weeks
Secondary uric acid Collect the patient's fasting blood to measure uric acid 0 week,4 weeks
Secondary Cys-C Collect the patient's fasting blood to measure Cys-C 0 week,4 weeks
Secondary fasting plasma glucose Collect the patient's fasting blood to measure fasting plasma glucose 0 week,4 weeks
Secondary HbA1c Collect the patient's fasting blood to measure HbA1c 0 week,4 weeks
Secondary total cholesterol Collect the patient's fasting blood to measure total cholesterol 0 week,4 weeks
Secondary Triglyceride Collect the patient's fasting blood to measure Triglyceride 0 week,4 weeks
Secondary HDL Collect the patient's fasting blood to measure HDL 0 week,4 weeks
Secondary LDL Collect the patient's fasting blood to measure LDL 0 week,4 weeks
Secondary albumin Collect the patient's fasting blood to measure albumin 0 week,4 weeks
Secondary Urinary microalbumin/urinary creatinine Collect random urine samples from patients to measure urine microalbumin/urinary creatinine(mg/g) 0 week,4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06006689 - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Phase 2
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians
Completed NCT03627715 - Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan Phase 2